Rongmei Zhang

发表

Performance evaluation of regression splines for propensity score adjustment in post-market safety analysis with multiple treatments

Yuxi Tian, Elande Baro, Rongmei Zhang, 2019, Journal of biopharmaceutical statistics.

Risk of Stroke and Bleeding in Atrial Fibrillation Treated with Apixaban Compared with Warfarin

D. Graham, M. Bradley, E. Eworuke, 2020, Journal of General Internal Medicine.

Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants

Mark S Levenson, C. Granger, R. Jin, 2022, JAMA network open.

The Use of Machine Learning in Regulatory Drug Safety Evaluation

Mark S Levenson, S. Dharmarajan, Yong Ma, 2022, Statistics in Biopharmaceutical Research.

Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice

D. Singer, A. Go, S. Sung, 2017, Annals of Internal Medicine.

A cohort study to assess risk of cutaneous small vessel vasculitis among users of different oral anticoagulants

E. Eworuke, A. Ajao, Rongmei Zhang, 2022, Pharmacoepidemiology and drug safety.

Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin

P. Waldron, H. Wong, E. Eworuke, 2021, Drug Safety.

Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.

M. Reichman, T. MaCurdy, D. Graham, 2019, The American journal of medicine.

Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation

Mark Levenson, Chris Worrall, Mark S Levenson, 2015, Circulation.

Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System

J. Gagne, M. Reichman, J. Nelson, 2018, Pharmacoepidemiology and drug safety.

Drug availability adjustments in population‐based studies of prescription opioid abuse

Rajdeep Gill, G. D. Dal Pan, J. Trinidad, 2017, Pharmacoepidemiology and drug safety.

Leveraging Case Narratives to Enhance Patient Age Ascertainment from Adverse Event Reports

E. Wu, Yong Ma, C. Kortepeter, 2021, Pharmaceutical Medicine.

Disparities in erythropoiesis-stimulating agent use after changes in medicare reimbursement and implementation of a risk evaluation and mitigation strategy

T. MaCurdy, D. Graham, J. Kelman, 2022, Drugs & Therapy Perspectives.

Trends in Erythropoiesis‐stimulating agent use and blood transfusions for chemotherapy‐induced anemia throughout FDA's risk evaluation and mitigation strategy lifecycle

T. MaCurdy, D. Graham, J. Kelman, 2021, Pharmacoepidemiology and drug safety.

Association of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death

David Croteau, Rongmei Zhang, Kelly Harbourt, 2020, Pharmacoepidemiology and drug safety.

Trends in oral and vaginally administered estrogen use among US women 50 years of age or older with commercial health insurance

S. R. Slaughter, W. Liu, J. Weissfeld, 2017, Menopause.

Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project

P. Wax, J. Devgun, K. Aldy, 2023, JAMA network open.

Evaluation of a natural language processing tool for extracting gender, weight, ethnicity, and race in the US food and drug administration adverse event reporting system

E. Wu, C. Kortepeter, M. Muñoz, 2022, Frontiers in Drug Safety and Regulation.

Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study

M. Reichman, A. Iyer, S. Lendle, 2017, Diabetes Care.